MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer

Journal of Oncology

Volumn , Issue , 2009, Pages

  Fountzilas, George ^a   Kalogera Fountzila, Anna ^a   Lambaki, Sophia ^a   Wirtz, Ralph M ^b   Nikolaou, Angelos ^a   Karayannopoulou, Georgia ^a   Bobos, Mattheos ^a   Kotoula, Vassiliki ^a   Murray, Samuel ^c   Lambropoulos, Alexandros ^d   Aravantinos, Gerasimos ^e   Markou, Konstantinos ^a   Athanassiou, Eleni ^f   Misailidou, Despina ^d   Kalogeras, Konstantine T ^a,g   Skarlos, Demosthenis ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b SIEMENS AG   (Germany)

^c METROPOLITAN HOSPITAL   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f Agios Savvas Cancer Hospital   (Greece)

^g Hellenic Cooperative Oncology Group   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GELATINASE B; PROTEIN P16; PROTEIN P53; SCATTER FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; AMNESIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRY SKIN; DYSPHAGIA; FATIGUE; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HOARSENESS; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUCLEOTIDE SEQUENCE; OTITIS; PAIN; PERIPHERAL NEUROPATHY; PREDICTION; PRURITUS; RASH; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 75449105597     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/305908     Document Type: Article

References (86)

1. Posner M., Evolving strategies for combined-modality therapy for locally advanced head and neck cancer Oncologist 2007 12 8 967 974 (Pubitemid 47359139)
2. Pignon J. P., Bourhis J., Domenge C., Design L., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data The Lancet 2000 355 9208 949 955
3. Forastiere A. A., Goepfert H., Maor M., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer New England Journal of Medicine 2003 349 22 2091 2098
4. Seiwert T. Y., Salama J. K., Vokes E. E., The concurrent chemoradiation paradigmgeneral principles Nature Clinical Practice Oncology 2007 4 2 86 100
5. Salama J. K., Seiwert T. Y., Vokes E. E., Chemoradiotherapy for locally advanced head and neck cancer Journal of Clinical Oncology 2007 25 26 4118 4126
6. Calais G., Alfonsi M., Bardet E., Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma Journal of the National Cancer Institute 1999 91 24 2081 2086
7. Fountzilas G., Tolis C., Kalogera-Fountzila A., Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group phase II study Medical Oncology 2005 22 3 269 279 (Pubitemid 41176323)
8. Schtze C., Drfler A., Eicheler W., Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma Strahlentherapie und Onkologie 2007 183 5 256 264
9. Ang K. K., Berkey B. A., Tu X., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Research 2002 62 24 7350 7356
10. Maurizi M., Almadori G., Ferrandina G., Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma British Journal of Cancer 1996 74 8 1253 1257
11. Almadori G., Cadoni G., Galli J., Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse International Journal of Cancer 1999 84 2 188 191
12. Akimoto T., Hunter N., Buchmiller L., Mason K., Ang K. K., Milas L., Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clinical Cancer Research 1999 5 10 2884 2890
13. Milas L., Mason K. A., Hunter N., Li C., Wallace S., Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability International Journal of Radiation Oncology Biology Physics 2003 55 3 707 712
14. Sancar A., Lindsey-Boltz L. A., Unsal-Kamaz K., Linn S., Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annual Review of Biochemistry 2004 73 39 85
15. Chen D. J., Nirodi C. S., The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage Clinical Cancer Research 2007 13 22 6555 6560
16. Huang S.-M., Bock J. M., Harari P. M., Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Research 1999 59 8 1935 1940
17. Huang S.-M., Harari P. M., Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clinical Cancer Research 2000 6 6 2166 2174
18. Thariat J., Milas L., Ang K. K., Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer International Journal of Radiation Oncology Biology Physics 2007 69 4 974 984
19. Nyati M. K., Morgan M. A., Feng F. Y., Lawrence T. S., Integration of EGFR inhibitors with radiochemotherapy Nature Reviews Cancer 2006 6 11 876 885
20. Dietl B., Marienhagen J., Schaefer C., Pohl F., Klbl O., Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging Strahlentherapie und Onkologie 2007 183 3 138 143
21. Studer G., Luetolf U. M., Glanzmann C., Locoregional failure analysis in head-and-neck cancer patients treated with IMRT Strahlentherapie und Onkologie 2007 183 8 417 423
22. Milas L., Mason K., Hunter N., In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clinical Cancer Research 2000 6 2 701 708
23. Bonner J. A., Harari P. M., Giralt J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New England Journal of Medicine 2006 354 6 567 578
24. Mendelsohn J., Fan Z., Epidermal growth factor receptor family and chemosensitization Journal of the National Cancer Institute 1997 89 5 341 343
25. De Herdt M.-J., Baatenburg de Jong R. J., HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma Frontiers in Bioscience 2008 13 7 2516 2526
26. Zamble D. B., Mu D., Reardon J. T., Sancar A., Lippard S. J., Repair of cisplatin-DNA adducts by the mammalian excision nuclease Biochemistry 1996 35 31 10004 10013 (Pubitemid 26269915)
27. Olaussen K. A., Dunant A., Fouret P., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy New England Journal of Medicine 2006 355 10 983 991
28. Quintela-Fandino M., Hitt R., Medina P. P., DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy Journal of Clinical Oncology 2006 24 26 4333 4339
29. Sengupta N., MacDonald T. T., The role of matrix metalloproteinases in stromal/epithelial interactions in the gut Physiology 2007 22 6 401 409
30. Zhang S., Li L., Lin J.-Y., Lin H., Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma World Journal of Gastroenterology 2003 9 5 899 904
31. Liu A., Garg P., Yang S., Epidermal growth factor-like repeats of thrombospondins activate phospholipase C and increase epithelial cell migration through indirect epidermal growth factor receptor activation Journal of Biological Chemistry 2009 284 10 6389 6402
32. Ahn G.-O., Brown J. M., Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells Cancer Cell 2008 13 3 193 205
33. Rubin Grandis J., Melhem M. F., Gooding W. E., Levels of TGF-and EGFR protein in head and neck squamous cell carcinoma and patient survival Journal of the National Cancer Institute 1998 90 11 824 832
34. Dabbs D. J., Diagnostic Immunohistochemistry 2002 1st Philadelphia, Pa, USA Churchill Livingstone
35. Skacel M., Skilton B., Pettay J. D., Tubbs R. R., Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data Applied Immunohistochemistry and Molecular Morphology 2002 10 1 1 6
36. Hanawa M., Suzuki S., Dobashi Y., EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus International Journal of Cancer 2006 118 5 1173 1180
37. Nakajima M., Sawada H., Yamada Y., The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 1999 85 9 1894 1902
38. Hafkamp H. C., Manni J. J., Haesevoets A., Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas International Journal of Cancer 2008 122 12 2656 2664
39. Resnick M. B., Routhier J., Konkin T., Sabo E., Pricolo V. E., Epidermal growth factor receptor, c-MET,-Catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study Clinical Cancer Research 2004 10 9 3069 3075
40. Gunduz M., Ouchida M., Fukushima K., Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers Oncogene 2002 21 28 4462 4470
41. Walch A., Bink K., Hutzler P., Sequential multilocus fluorescence in situ hybridization can detect complex patterns of increased gene dosage at the single cell level in tissue sections Laboratory Investigation 2001 81 10 1457 1459
42. Chung C. H., Ely K., McGavran L., Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas Journal of Clinical Oncology 2006 24 25 4170 4176
43. Cappuzzo F., Hirsch F. R., Rossi E., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer Journal of the National Cancer Institute 2005 97 9 643 655 (Pubitemid 40812628)
44. Koutras A. K., Kalogeras K. T., Dimopoulos M.-A., Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study British Journal of Cancer 2008 99 11 1775 1785
45. Zhou W., Gurubhagavatula S., Liu G., Excision repair cross- complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clinical Cancer Research 2004 10 15 4939 4943
46. Murray S., Timotheadou E., Linardou H., Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients Lung Cancer 2006 52 2 225 233
47. Fountzilas G., Bobos M., Kalogera-Fountzila A., Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation Cancer Investigation 2008 26 8 784 793
48. Ogura H., Watanabe S., Fukushima K., Masuda Y., Fujiwara T., Yabe Y., Presence of human papillomavirus type 18 DNA in a pharyngeal and a laryngeal carcinoma Japanese Journal of Cancer Research 1991 82 11 1184 1186
49. Kyzas P. A., Evangelou E., Denaxa-Kyza D., Ioannidis J. P., 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis Journal of the National Cancer Institute 2008 100 10 712 720
50. Yao M., Graham M. M., Smith R. B., Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report International Journal of Radiation Oncology Biology Physics 2004 60 5 1410 1418
51. Corry J., Rischin D., Hicks R. J., Peters L. J., The role of PET-CT in the management of patients with advanced cancer of the head and neck Current Oncology Reports 2008 10 2 149 155
52. Pfister D. G., Su Y. B., Kraus D. H., Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm Journal of Clinical Oncology 2006 24 7 1072 1078
53. Bentzen S. M., Atasoy B. M., Daley F. M., Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial Journal of Clinical Oncology 2005 23 24 5560 5567
54. Chua D. T., Nicholls J. M., Sham J. S., Au G. K., Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy International Journal of Radiation Oncology Biology Physics 2004 59 1 11 20
55. Fukuoka M., Yano S., Giaccone G., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer Journal of Clinical Oncology 2003 21 12 2237 2246
56. Burtness B., Goldwasser M. A., Flood W., Mattar B., Forastiere A. A., Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study Journal of Clinical Oncology 2005 23 34 8646 8654
57. Cohen E. E., Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology 2006 24 17 2659 2665
58. Temam S., Kawaguchi H., El-Naggar A. K., Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer Journal of Clinical Oncology 2007 25 16 2164 2170
59. Wirth L. J., Haddad R. I., Lindeman N. I., Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology 2005 23 28 6976 6981
60. Cohen E. E., Lingen M. W., Martin L. E., Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR Clinical Cancer Research 2005 11 22 8105 8108
61. Lynch T. J., Bell D. W., Sordella R., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New England Journal of Medicine 2004 350 21 2129 2139
62. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma European Journal of Cancer 2006 42 1 109 111
63. Lee J. W., Soung Y. H., Kim S. Y., Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck Clinical Cancer Research 2005 11 8 2879 2882
64. Zucali P. A., Ruiz M. G., Giovannetti E., Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Annals of Oncology 2008 19 9 1605 1612
65. Cappuzzo F., Jnne P. A., Skokan M., MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients Annals of Oncology 2009 20 2 298 304
66. Handra-Luca A., Hernandez J., Mountzios G., Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma Clinical Cancer Research 2007 13 13 3855 3859
67. Fountzilas G., Bamias A., Kalogera-Fountzila A., Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck Anticancer Research 2009 29 2 529 538
68. Dnne A. A., Mandic R., Falkenberg S., Dalchow C. V., Sesterhenn A. M., Werner J. A., RT-PCR expression profiling of matrix metalloproteinases and their specific inhibitors in cell lines and fresh biopsies of squamous cell carcinomas of the head and neck In Vivo 2005 19 5 943 948
69. Bindhu O. S., Ramadas K., Sebastian P., Pillai M. R., High expression levels of nuclear factor kappa B and gelatinase in the tumorigenesis of oral squamous cell carcinoma Head and Neck 2006 28 10 916 925
70. Krivak T. C., Darcy K. M., Tian C., Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer Journal of Clinical Oncology 2008 26 21 3598 3606
71. Beroukhim R., Lin M., Park Y., Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays PLoS Computational Biology 2006 2 5, article e41
72. Mort R., Mo L., McEwan C., Melton D. W., Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer British Journal of Cancer 2003 89 2 333 337
73. Haddad R. I., Shin D. M., Recent advances in head and neck cancer New England Journal of Medicine 2008 359 11 1143 1154
74. Psyrri A., DiMaio D., Human papillomavirus in cervical and head-and-neck cancer Nature Clinical Practice Oncology 2008 5 1 24 31
75. Weinberger P. M., Yu Z., Haffty B. G., Molecular classification identifies a subset of human papillomavirusassociated oropharyngeal cancers with favorable prognosis Journal of Clinical Oncology 2006 24 5 736 747
76. Termine N., Panzarella V., Falaschini S., HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (19882007) Annals of Oncology 2008 19 10 1681 1690
77. Romanitan M., Nsman A., Ramqvist T., Human papillomavirus frequency in oral and oropharyngeal cancer in Greece Anticancer Research 2008 28 4 2077 2080
78. Vlachtsis K., Nikolaou A., Markou K., Fountzilas G., Daniilidis I., Clinical and molecular prognostic factors in operable laryngeal cancer European Archives of Otorhinolaryngol 2005 262 11 890 898
79. Lindel K., Beer K. T., Laissue J., Greiner R. H., Aebersold D. M., Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma Cancer 2001 92 4 805 813
80. Hafkamp H. C., Speel E. J., Haesevoets A., A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 58 International Journal of Cancer 2003 107 3 394 400
81. Begum S., Cao D., Gillison M., Zahurak M., Westra W. H., Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma Clinical Cancer Research 2005 11 16 5694 5699
82. Smeets S. J., Hesselink A. T., Speel E.-J., A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen International Journal of Cancer 2007 121 11 2465 2472
83. Bianchini D., Jayanth A., Yu J. C., Cunningham D., Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker Clinical Colorectal Cancer 2008 7 1 33 43
84. Baselga J., Trigo J. M., Bourhis J., Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck Journal of Clinical Oncology 2005 23 24 5568 5577
85. Herbst R. S., Arquette M., Shin D. M., Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck Journal of Clinical Oncology 2005 23 24 5578 5587
86. Blke E., Gerber P. A., Lammering G., Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab Strahlentherapie und Onkologie 2008 184 2 105 110